Strybol Iben Pharma
ActiveSummary
Strybol Iben Pharma has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €158,240 and a net result of €147,626. Equity has been growing by about 19% per year since 2022. Its solvency ranks better than 18% of 12,777 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Overview
Official details
Source: KBO- Status
- Active since 12-04-2021 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730and 1 other
- Establishment unit
- 2.317.267.939 9990 Maldegem, since 12-04-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 30-01-2025
Board and ownership
Board
- Strybol IbenDirector · since 12-04-2021
- Holdings
- Shares in 7 companies including STRYBOL DE ZEVEN TORENTJES and STRYBOL SINT-TRUDO
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.6%
Annual accounts 2025
- Gross margin
- €222,904
- ▲ 421%
- Turnover
- ≈ €1.0m
- estimated
- Profit
- €147,626
- ▲ 413%
- Equity
- €158,240
- ▲ 2.4%
- Total assets
- €2.2m
- ▲ 12×
Score breakdownraises riskEquity €158,240 (7.3% of total assets)Sector: Retail trade (NACE 47)Founded in 2021lowers riskSize: total assets €2.2mShow the evidence
Checked score
Score 2025
70
/ 100
Healthy
Probability in this band: 0.55% to 1.5%
Financially stronger than 49% of small companies in retail trade (NACE 47)
Financial strength · tick: 2024
Average
Solvency
32-68
equity 7.3% of total assets
Liquidity
48-48
short-term debt 15.3% · cash 1.0%
Profitability
77-11
return on assets 6.8%
Bankruptcy probability within 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.2%▲ +0.1 percentage points vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.6%▲ +0.4 percentage points vs 07-2026
09-2026: 0.6%● unchanged vs 08-2026
10-2026: 0.6%● unchanged vs 09-2026highest value
11-2026: 0.6%● unchanged vs 10-2026highest value
Credit of up to €11,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.37 (3.24 in 2024), below 1. Short-term debt is 15.3% and cash 1% of total assets. 92.7% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, small). It does better than 19% of them on solvency, 58% on liquidity, 72% on profitability and 47% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 18% of 12777 sector peers (2025).
NBB · sector comparisonPosition among 12777 sector peers
Solvency
better than 18%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
29 days early
2024
9 days early
2023
1 day early
2022
24 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 4 accounts on average 16 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 15 July (4 of the last 4 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
Recent changes
- · Gazette deed General meeting · Capital contribution
- · Gazette deed Director appointment · Other provision
- · Gazette deed Annual general meeting · Amendment of the articles
Companies linked to Strybol Iben Pharma
Comparable companies
These companies have the same main activity as Strybol Iben Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.6m and €2.1m, founded between 2018 and 2023.
| Company | Total assets | Gross margin |
|---|---|---|
| Strybol Iben Pharma Maldegem | €2.2m | €0.2m |
| Varmaca Peer | €2.0m | €0.3m |
| PHARMACIE HERBINT Evere | €1.8m | €0.3m |
| APR.P.D. Hasselt | €2.1m | €0.2m |
| K-FARMA Zandhoven | €1.9m | €0.2m |
| CASSART PHARMA Silly | €1.7m | €0.1m |
| SEPHALIN Veurne | €1.6m | €0.2m |
Key facts about Strybol Iben Pharma
- What is the company number of Strybol Iben Pharma?
- The company number of Strybol Iben Pharma is 0766.610.695. The VAT number is the same number with BE in front: BE 0766.610.695.
- Where is Strybol Iben Pharma based?
- The registered office is at Donkstraat 120A, 9990 Maldegem.Company details
- What does Strybol Iben Pharma do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Strybol Iben Pharma?
- The legal form of Strybol Iben Pharma is Private limited company (BV).
- When was Strybol Iben Pharma founded?
- Strybol Iben Pharma was founded on 12-04-2021.
- Is Strybol Iben Pharma still active?
- Yes, Strybol Iben Pharma is an active enterprise in the KBO register.
- What is the turnover of Strybol Iben Pharma?
- The turnover in financial year 2025 is ≈ €1.0m. This figure is estimated from the gross margin of €222,904 and 51 comparable companies (NACE 477). It probably lies between €710,000 and €2.0m.Financials
- Is Strybol Iben Pharma profitable?
- In financial year 2025, Strybol Iben Pharma made a profit of €147,626.
- Where can I find the annual accounts of Strybol Iben Pharma?
- Strybol Iben Pharma filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Strybol Iben Pharma due?
- Strybol Iben Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.